Hostname: page-component-78c5997874-8bhkd Total loading time: 0 Render date: 2024-11-07T22:17:53.588Z Has data issue: false hasContentIssue false

Treatment of aggression with topiramate in male borderline patients, part II: 18-month follow-up

Published online by Cambridge University Press:  16 April 2020

Marius K. Nickel*
Affiliation:
Clinic for Psychosomatic Medicine and Psychotherapy, Sommersbergseestrasse 395, Medical University of Graz, 8990Bad Aussee, Austria University Clinic for Psychiatry 1, PMU, Salzburg, Austria
Thomas H. Loew
Affiliation:
Department of Psychosomatic Medicine, University Clinic, Regensburg, Germany
*
*Corresponding author. Clinic for Psychosomatic Medicine and Psychotherapy, Sommersbergseestrasse 395, Medical University of Graz, 8990 Bad Aussee, Austria. Tel.: +43 3622 521003203. E-mail address: [email protected] (M.K. Nickel).
Get access

Abstract

Objective

We previously tested topiramate, an anticonvulsant, in the treatment of aggression in men with borderline personality disorder (BPD) (Nickel M, Nickel C, Kaplan P, Lahmann C, Mühlbacher M, Tritt K, et al. Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry 2005;57:495–9), and found significant changes on most scales of the state–trait anger expression inventory (STAXI) and significant weight loss eight weeks later. The aim of this trial was to assess topiramate's efficacy in the long-term therapy for aggression in men with BPD.

Methods

This 18-month follow-up observation, in which the previous patients (topiramate group: n = 22; former placebo group: n = 22) were examined bianually, was carried out.

Results

According to the intent-to-treat principle, significant changes on all scales of the STAXI were observed in the subjects treated with topiramate. Additional significant weight loss was observed. All subjects tolerated topiramate relatively well.

Conclusions

Topiramate appears to be an effective, relatively safe agent in the long-term treatment of patients with BPD. Mild, non-transient weight loss can be expected.

Type
Short communication
Copyright
Copyright © Elsevier Masson SAS 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bozikas, V.P., Petrikis, P., Kourtis, A., Youlis, A., Karavatos, A.Treatment of acute mania with topiramate in hospitalized patients. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:12031206.CrossRefGoogle ScholarPubMed
De Bruijn, E.R., Grootens, K.P., Verkes, R.J., Buchholz, V., Hummelen, J.W., Hulstijn, W.Neural correlates of impulsive responding in borderline personality disorder: ERP evidence for reduced action monitoring. J Psychiatr Res 2006;40:428437.CrossRefGoogle ScholarPubMed
Janowsky, D.S., Kraus, J.E., Barnhill, J., Elamir, B., Davis, J.M.Effects of topiramate on aggressive, self-injurious, and disruptive/destructive behaviors in the intellectually disabled: an open-label retrospective study. J Clin Psychopharmacol 2003;23:500504.CrossRefGoogle Scholar
Loew, T., Nickel, M., Kaplan, P., Nickel, C., Muehlbacher, M., Kettler, C.et al.Topiramate treatment of women with borderline personality disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol 2006;26:6166.CrossRefGoogle ScholarPubMed
Muehlbacher, M., Nickel, C., Nickel, M., Tritt, K., Lahmann, C., Leiberich, P.K.et al.Topiramate in treatment of patients with chronic low back pain: a randomized, double-blind, placebo-controlled study. Clin J Pain 2006;22:526531.CrossRefGoogle ScholarPubMed
Nickel, C., Tritt, K., Muehlbacher, M., Pedrosa Gil, F., Mitterlehner, F.O., Kaplan, P.et al.Topiramate treatment in bulimia nervosa patients: a randomized controlled trial. Int J Eat Disord 2005;38:295300.CrossRefGoogle Scholar
Nickel, M., Nickel, C., Kaplan, P., Lahmann, C., Mühlbacher, M., Tritt, K.et al.Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry 2005;57:495499.CrossRefGoogle ScholarPubMed
Nickel, M.K., Nickel, C., Mitterlehner, F.O., Tritt, K., Lahmann, C., Leiberich, P.et al.Topiramate treatment of aggression in female borderline personality disorder patients: a double blind, placebo-controlled study. J Clin Psychiatry 2004;65:15151519.CrossRefGoogle ScholarPubMed
Schwenkmezger, P., Hodapp, V., Spielberger, C.D.Das state-trait-aergerausdrucks-inventar. Bern, Goettingen, Toronto: Huber; 1992.Google Scholar
Stevens, J.Applied multivariate statistics for the social sciences. New Jersey: Erlbaum; 1992.Google Scholar
Tariot, P.N., Erb, R., Podgorski, C.A., Cox, C., Patel, S., Jakimovich, L.et al.Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998;155:5461.CrossRefGoogle ScholarPubMed
Teter, C.J., Early, J.J., Gibbs, C.M.Treatment of affective disorder and obesity with topiramate. Ann Pharmacother 2000;34:12621265.CrossRefGoogle ScholarPubMed
Thompson, P.J., Baxendale, S.A., Duncan, J.S., Sander, J.W.A.S.Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry 2000;69:636641.CrossRefGoogle ScholarPubMed
Tritt, K., Nickel, C., Lahmann, C., Leiberich, P.K., Rother, W.K., Loew, T.H.et al.Lamotrigine treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. J Psychopharmacol 2005;19:287291.CrossRefGoogle ScholarPubMed
White, H.S., Brown, S.D., Woodhead, J.H., Skeen, G.A., Wolf, H.H.Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res 1997;28:167179.CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.